The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy
Status: Recruiting
Location: See location...
Intervention Type: Combination product
Study Type: Observational
SUMMARY
This study will determine how the intestinal microbiome differs between patients with obesity and early triple-negative breast cancer who achieve a pathologic complete response from preoperative anti-PD-1 immunotherapy (pembrolizumab) versus patients who do not.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:
• Age ≥18 years
• Female biological sex
• Newly diagnosed, previously untreated, histologically confirmed early triple-negative breast cancer
• Plan to initiate preoperative anti-PD-1 immunotherapy using pembrolizumab
• Overweight or obesity, defined as a body mass index \>=25 kg/m2
• Ability to provide written informed consent
• Allow the collection and storage of biospecimens and data for future use
Locations
United States
Louisiana
Pennington Biomedical Research Center
RECRUITING
Baton Rouge
Contact Information
Primary
Justin Brown, Ph.D.
justin.brown@pbrc.edu
225-763-3000
Time Frame
Start Date: 2024-03-11
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 25
Related Therapeutic Areas
Sponsors
Leads: Pennington Biomedical Research Center